View Single Post
  #6  
Old Mon Aug 16, 2010, 11:40 AM
Birgitta-A Birgitta-A is offline
Member
 
Join Date: Oct 2007
Location: Stockholm, Sweden
Posts: 1,918
Promacta

Now I have read the article "Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome."

The reseachers have not studied the effect of Promacta on MDS patients - only on bone marrow cells from low risk MDS patients - the same kind of study that has been carried out on high risk patients.

Promacta may stimulate all stages of megakaryopoiesis (fabrication of megacaryocytes which make platelets) in cell lines. They did not observe any significant change in the proliferation rate of patient blast cells that might clinically imply an increase risk for AML transformation.
Kind regards
Birgitta-A
Reply With Quote